COMMUNIQUÉS West-GlobeNewswire

American Postal Workers Union Health Plan Selects Inovalon ONE® Platform

17/01/2019 - 13:55

Partnership Focuses on Leveraging Advanced Analytics and Technologies to Improve Quality and Financial Performance BOWIE, Md. , Jan. 17, 2019 (GLOBE NEWSWIRE) -- Inovalon (Nasdaq: INOV), a leading technology company [...]

Ossur Hf : Q4&FY 2018 Results - Conference call Tuesday 5 February at 9:00 CET

17/01/2019 - 13:43

Announcement no. 03/2018 17 January 2019 Conference call on Tuesday 5 February at 9:00 CET / 8:00 GMT / 3:00 EDT Össur will publish its financial results for Q4&FY 2018 prior to market opening on Tuesday 5 February [...]

ProMIS Neurosciences to Participate in NobleCon15 and CanTech Investment Conferences

17/01/2019 - 13:30

Company to showcase its innovative Alzheimer’s, Parkinson’s and ALS programs TORONTO and CAMBRIDGE, Mass., Jan. 17, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company [...]

Moleculin Announces Dr. James L. Abbruzzese, Chief of Medical Oncology Division at Duke University, Joins Science Advisory Board

17/01/2019 - 13:30

Dr. Abbruzzese to add significant pancreatic cancer expertise to advance drug development HOUSTON, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical [...]

Lexicon Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Review Sotagliflozin New Drug Application for the Treatment of Type 1 Diabetes

17/01/2019 - 13:05

THE WOODLANDS, Texas, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that NASDAQ has halted trading of the company’s common stock. The U.S. Food and Drug Administration’s [...]

First Patient Dosed in Phase 1 Clinical Trial Evaluating Neoepitopes Formulated in IMV’s DPX Delivery Platform in Ovarian Cancer Patients

17/01/2019 - 13:05

DARTMOUTH, Nova Scotia, Jan. 17, 2019 (GLOBE NEWSWIRE) -- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that the first patient has been treated in the Phase 1 trial [...]

HEXO to begin trading on the NYSE American

17/01/2019 - 13:00

GATINEAU, Quebec, Jan. 17, 2019 (GLOBE NEWSWIRE) -- HEXO Corp. (“HEXO” or the “Company”) (TSX: HEXO ) is pleased to announce that its common shares have been approved for listing on the NYSE American LLC ("NYSE American [...]

Début des négociations des actions d’HEXO au NYSE American

17/01/2019 - 13:00

GATINEAU, Québec, 17 janv. 2019 (GLOBE NEWSWIRE) -- HEXO Corp. (« HEXO » ou la « Société ») (TSX: HEXO ) a le plaisir d’annoncer que l’inscription de ses actions ordinaires au NYSE American LLC (« NYSE American ») a été [...]

AVROBIO, Inc. Announces Analyst and Investor Event and Upcoming Clinical Data Presentations at WORLDSymposium 2019

17/01/2019 - 13:00

Analyst and Investor Event to be Webcast on Wednesday, February 6, 2019 at 6:30 p.m. ET CAMBRIDGE, Mass., Jan. 17, 2019 (GLOBE NEWSWIRE) -- AVROBIO, Inc . (NASDAQ: AVRO) (the “Company”), a Phase 2 clinical-stage gene [...]

Zafgen Announces Positive Results for Second Cohort of Phase 2 Clinical Trial of ZGN-1061

17/01/2019 - 13:00

Data for the 1.8 mg dose demonstrated meaningfully greater efficacy than the 0.9 mg dose Cohort 2 data showed statistically and clinically significant 1.1% reduction of A1C at the 1.8 mg dose relative to placebo [...]

ContraFect Announces Additional $2.3 Million in Funding from CARB-X to Support Gram-Negative Lysin Program

17/01/2019 - 13:00

YONKERS, N.Y., Jan. 17, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX) , a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life- [...]

Avivagen Announces CEO Letter to Shareholders

17/01/2019 - 12:30

OTTAWA, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV) (“Avivagen”) is pleased to announce its 2019 letter to shareholders by Chairman and interim CEO Kym Anthony. To our shareholders: As the consumer, [...]

Interim report September 1, 2018 – November 30, 2018

17/01/2019 - 08:01

Company announcement no.01/2019 Report attached For further information, please contact: Martin Riise, Head of Investor Relations, Tel: +45 53 39 22 50 Camilla Lercke, Head of Media Relations, Tel: +45 53 39 23 84 About [...]

PledPharma presents PledOx®’s phase III program at the Gastrointestinal (GI) Cancers Symposium

17/01/2019 - 08:00

Stockholm, January 17, 2019. PledPharma AB (publ) announces that the company’s global phase III program, POLAR, has been accepted for a poster presentation during the Gastrointestinal (GI) Cancers Symposium in January [...]

Nicox : Point d'activité et résumé financier du quatrième trimestre 2018

17/01/2019 - 07:31

Communiqué de presse Nicox : Point d'activité et résumé financier du quatrième trimestre 2018 ................................................. Augmentation de 47% du nombre total de prescriptions de VYZULTA ® pour le [...]

DBV Technologies: Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF

17/01/2019 - 07:31

AMF REGULATED INFORMATION Montrouge, France, January 17, 2019 Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), [...]

DBV Technologies : Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF

17/01/2019 - 07:31

Informations Réglementées Montrouge, France, le 17 janvier (7h30 CET), 2019 Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF DBV Technologies (Euronext : DBV - ISIN : FR0010417345 - Nasdaq : DBVT [...]

Nicox Fourth Quarter 2018 Business Update and Financial Highlights

17/01/2019 - 07:31

Press Release Nicox Fourth Quarter 2018 Business Update and Financial Highlights ............................................... Total VYZULTA ® prescriptions for the fourth quarter 2018 up 47% compared to the third [...]

Spineway: 2018 revenue of €6.5M

17/01/2019 - 07:00

In thousands of euros 2017 2018* Annual revenue 9 137 6 513 * Unaudited figures The SPINEWAY Group posted a total 2018 revenue of €6 513K that is in line with the trend set by the previous quarters (-29%) pursuant to [...]